Serious Adverse Event Periodic Reporting Increased 20% In 2004, FDAer Says
Executive Summary
Serious adverse event periodic reports received by the Center for Drug Evaluation & Research increased 20% in 2004, FDA Investigator Thomas Berry said
You may also be interested in...
FDA Expects Increasing Flow Of Adverse Event Reports
FDA expects the Center for Drug Evaluation & Research to receive 17% more adverse reaction reports in fiscal year 2006 than it received in FY 2004
Vintage receives warning letter
Vintage Pharmaceuticals has failed to fulfill post-marketing adverse event reporting commitments, a May 26 FDA 1warning letter states. "Our inspection revealed that your firm had never submitted an [adverse drug experience] to FDA" for any ANDA, the letter states. The company said it submitted a response to FDA and views the matter as closed...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011